Last reviewed · How we verify
Infusion of MCARH109 T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Infusion of MCARH109 T cells (Infusion of MCARH109 T cells) — Memorial Sloan Kettering Cancer Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Infusion of MCARH109 T cells TARGET | Infusion of MCARH109 T cells | Memorial Sloan Kettering Cancer Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Infusion of MCARH109 T cells CI watch — RSS
- Infusion of MCARH109 T cells CI watch — Atom
- Infusion of MCARH109 T cells CI watch — JSON
- Infusion of MCARH109 T cells alone — RSS
Cite this brief
Drug Landscape (2026). Infusion of MCARH109 T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/infusion-of-mcarh109-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab